Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Merck and : NOXXON announces its participation in two french investor conferences in October 2017

share with twitter share with LinkedIn share with facebook
share via e-mail
10/02/2017 | 10:18am CEST

Release date- 29092017 - Berlin, Germany - NOXXON Pharma N.V. (EuroNext Growth Paris: ALNOX), a biotechnology company focused on improving cancer treatments by targeting the tumor microenvironment (TME), announced that it would participate in two conferences focused on institutional investors in October in Paris.

NOXXON will present at the French Financial Analysts Society / Societe Francaise des Analystes Financiers (SFAF) on October 3, 2017 at 10:00am at 135 boulevard Haussmann, 75008 Paris in the 'Salle Hausmann'.

NOXXON will also participate in the CF&B Large & Midcap Event which will take place on the 4th and 5th of October 2017 at the Palais Brongiart, 28 Place de la Bourse, 75002 Paris. NOXXON pharma will be available for meetings with institutional investors.


Tel: +49 (0) 30 726 247 0

Email: [email protected]


NOXXON Pharma N.V. is a clinical-stage biopharmaceutical company focused on cancer treatment. NOXXON's goal is to significantly enhance the effectiveness of cancer treatments including immunooncology approaches (such as immune checkpoint inhibitors) and current standards of care (such as chemotherapy and radiotherapy).

NOXXON's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its lead cancer drug candidate NOX-A12 (olaptesed pegol), which is the subject of a clinical immuno-oncology collaboration agreement with Merck & Co. / MSD (NYSE: MRK) to study NOX-A12 combined with Merck & Co.'s anti-PD-1 checkpoint-inhibiting antibody Keytruda (pembrolizumab) in pancreatic and colorectal cancer. The clinical trial testing NOX-A12 as monotherapy and in combination with Keytruda is being conducted at one of the leading centers for cancer research and treatment, the National Center for Tumor Diseases in Heidelberg, Germany. NOXXON is supported by a strong group of leading international investors, including TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, DEWB, NGN and Seventure. NOXXON has its statutory seat in Amsterdam, the Netherlands and its office in Berlin, Germany.


Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial indicators, developments of the financial situation or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for updating such information, which only represents the state of affairs on the day of publication.

(c) 2017 Electronic News Publishing -, source ENP Newswire

Stocks mentioned in the article
ChangeLast1st jan.
NOXXON PHARMA NV 10.00% 2.42 Real-time Quote.-61.89%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK AND COMPANY
06/15MERCK AND : Modern Alchemists Are Making Chemistry Greener
06/15MERCK AND : `s Keytruda snags I-O`s first cervical cancer nod to back up HPV fig..
06/15MERCK AND : FDA Grants Priority Review to Merck's Supplemental Biologics License..
06/15MERCK AND : FDA Approves Merck's KEYTRUDA for Treatment of Refractory or Relapse..
06/14MERCK AND : FDA Approves Merck's KEYTRUDA for Previously Treated Patients with R..
06/14MERCK AND : rebuts petition urging SCOTUS to ignore Fosamax appeal
06/14MERCK AND COMPANY : Ex-dividend day for
06/13MERCK AND : FDA Approves Merck’s KEYTRUDA® (pembrolizumab) for Treatment o..
06/13MERCK AND : Gets FDA Priority Review for Expanded Gardasil Age Range
06/13MERCK AND : FDA Grants Priority Review to Merck’s Supplemental Biologics L..
More news
News from SeekingAlpha
06/173 THINGS IN BIOTECH, JUNE 16 : Do You Know Anything About EHA? 
06/16Dynavax Gives A Welcome Business Update 
06/163 THINGS IN BIOTECH, JUNE 15 : Keep Rolling, Pembro 
06/15Avoiding The 'Black Hole' Of Disease Development 
06/15YOUR DAILY PHARMA SCOOP : Wright Receives PMA, Allergan And Corbus Report Positi.. 
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,14%
P/E ratio 2018 23,87
P/E ratio 2019 16,14
EV / Sales 2018 4,34x
EV / Sales 2019 4,14x
Capitalization 167 B
Duration : Period :
Merck and Company Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Technical analysis trends MERCK AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 69,1 $
Spread / Average Target 11%
EPS Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis CFO & Executive Vice President-Global Services
Thomas Henry Glocer Independent Director
Rochelle B. Lazarus Independent Director
Leslie A. Brun Lead Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
MERCK AND COMPANY10.24%166 880
JOHNSON & JOHNSON-12.21%328 858
PFIZER-0.17%212 690
NOVARTIS-8.25%193 446
ROCHE HOLDING LTD.-14.06%183 969
AMGEN6.39%122 422